WO2001023562A3 - Osteoprotegerin regulatory region - Google Patents

Osteoprotegerin regulatory region Download PDF

Info

Publication number
WO2001023562A3
WO2001023562A3 PCT/US2000/026497 US0026497W WO0123562A3 WO 2001023562 A3 WO2001023562 A3 WO 2001023562A3 US 0026497 W US0026497 W US 0026497W WO 0123562 A3 WO0123562 A3 WO 0123562A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
opg
bone
regulatory region
cartilage
Prior art date
Application number
PCT/US2000/026497
Other languages
French (fr)
Other versions
WO2001023562A2 (en
WO2001023562A9 (en
Inventor
Srinivasan Chandrasekhar
David Lloyd Halladay
Thomas John Martin
Rebecca Ruth Miles
Jude Empka Onyia
Kannan Thirunavukkarasu
Original Assignee
Lilly Co Eli
Srinivasan Chandrasekhar
David Lloyd Halladay
Thomas John Martin
Rebecca Ruth Miles
Jude Empka Onyia
Kannan Thirunavukkarasu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Srinivasan Chandrasekhar, David Lloyd Halladay, Thomas John Martin, Rebecca Ruth Miles, Jude Empka Onyia, Kannan Thirunavukkarasu filed Critical Lilly Co Eli
Priority to AU77206/00A priority Critical patent/AU7720600A/en
Publication of WO2001023562A2 publication Critical patent/WO2001023562A2/en
Publication of WO2001023562A9 publication Critical patent/WO2001023562A9/en
Publication of WO2001023562A3 publication Critical patent/WO2001023562A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention provides the complete transcriptional regulatory region of the human opg gene. The disclosed sequence, fragments thereof, and functional variants thereof, can be used in methods for regulating osteoclastogenesis, and treating bone diseases and other diseases caused by over- or under-expession of osteoprotegerin. The disclosed sequences are also useful in diagnosing patient susceptibility to developing OPG-related bone, cartilage, immune, and arterial diseases, and for diagnosing patient receptivity to treatment with drugs for such diseases. Methods for identifying compounds that modulate osteoclast formation, bone resorption, and other OPG-related bone, cartilage, immune, and arterial diseases are also provided.
PCT/US2000/026497 1999-09-27 2000-09-26 Osteoprotegerin regulatory region WO2001023562A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU77206/00A AU7720600A (en) 1999-09-27 2000-09-26 Osteoprotegerin regulatory region

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15580399P 1999-09-27 1999-09-27
US60/155,803 1999-09-27

Publications (3)

Publication Number Publication Date
WO2001023562A2 WO2001023562A2 (en) 2001-04-05
WO2001023562A9 WO2001023562A9 (en) 2001-07-12
WO2001023562A3 true WO2001023562A3 (en) 2002-01-24

Family

ID=22556858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026497 WO2001023562A2 (en) 1999-09-27 2000-09-26 Osteoprotegerin regulatory region

Country Status (2)

Country Link
AU (1) AU7720600A (en)
WO (1) WO2001023562A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816380A1 (en) * 1995-02-20 1998-01-07 Snow Brand Milk Products Co., Ltd. Novel protein and methods for the production of the same
EP0874045A1 (en) * 1996-08-19 1998-10-28 Snow Brand Milk Products Co., Ltd. Novel dnas and process for producing proteins by using the same
WO2000042216A2 (en) * 1999-01-18 2000-07-20 Osteometer Biotech A/S Genetic predisposition to abnormal calcification conditions
WO2001004137A1 (en) * 1999-07-09 2001-01-18 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
WO2001007611A2 (en) * 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
WO2001023559A1 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoclast differentiation factor regulatory region

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816380A1 (en) * 1995-02-20 1998-01-07 Snow Brand Milk Products Co., Ltd. Novel protein and methods for the production of the same
EP0874045A1 (en) * 1996-08-19 1998-10-28 Snow Brand Milk Products Co., Ltd. Novel dnas and process for producing proteins by using the same
WO2000042216A2 (en) * 1999-01-18 2000-07-20 Osteometer Biotech A/S Genetic predisposition to abnormal calcification conditions
WO2001004137A1 (en) * 1999-07-09 2001-01-18 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
WO2001007611A2 (en) * 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
WO2001023559A1 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoclast differentiation factor regulatory region

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRANDSTROM H ET AL: "POLYMORPHISM IN THE PROMOTER REGION OF THE HUMAN GENE FOR OSTEOPROTEGERIN: CORRELATION WITH BONE MINERAL DENSITY", JOURNAL OF BONE AND MINERAL RESEARCH,NEW YORK, NY,US, vol. 14, no. SUPPL. 01, September 1999 (1999-09-01), pages S334, XP000915449, ISSN: 0884-0431 *
DATABASE EMBL SEQUENCE DATABSE Hinxton, GB; 6 August 1998 (1998-08-06), T. MORINAGA: "Homo sapiens gene for osteoclstogenesis inhibitory factor, exon 1", XP002169892 *
HOFBAUER L C ET AL: "OSTEOPROTEGERIN AND ITS COGNATE LIGAND: A NEW PARADIGM OF OSTEOCLASTOGENESIS", EUROPEAN JOURNAL OF ENDOCRINOLOGY,NO,SCANDINAVIAN UNIVERSITY PRESS, vol. 139, no. 2, August 1998 (1998-08-01), pages 152 - 154-190, XP000876579, ISSN: 0804-4643 *
LACEY D L ET AL: "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 93, no. 2, 17 April 1998 (1998-04-17), pages 165 - 176, XP002117567, ISSN: 0092-8674 *
MORINAGA TOMONORI ET AL: "Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 254, no. 3, June 1998 (1998-06-01), pages 685 - 691, XP002934581, ISSN: 0014-2956 *
SIMONET W ET AL: "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density", CELL,US,CELL PRESS, CAMBRIDGE, NA, no. 89, 18 April 1997 (1997-04-18), pages 309 - 319, XP002077048, ISSN: 0092-8674 *
YASUDA HISATAKA ET AL: "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.", ENDOCRINOLOGY, vol. 139, no. 3, March 1998 (1998-03-01), pages 1329 - 1337, XP002934584, ISSN: 0013-7227 *

Also Published As

Publication number Publication date
AU7720600A (en) 2001-04-30
WO2001023562A2 (en) 2001-04-05
WO2001023562A9 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
IS7770A (en) Neutralizing antibodies against GDF-8 and their use
WO2004022580A3 (en) Bh3 peptides and method of use thereof
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
BR0011000A (en) Methods to prevent or treat a disease associated with ab amyloid deposits in a patient's brain, to evaluate an antibody for the removal activity of a biological entity physically associated with an antigen and to detect an amyloid deposit in a patient, pharmaceutical composition, and, diagnostic set
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
ATE182180T1 (en) LAMANINE CHAINS: DIAGNOSTIC AND THERAPEUTIC USE
DE69832688D1 (en) HIGH-LIQUID BUTYRYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT AND DIAGNOSIS OF DEMENTIA AND ALZHEIMERS ILLNESS
DE60319103D1 (en) SUBSTANCES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
ATE356995T1 (en) METHOD FOR IDENTIFYING AGENTS FOR TREATING DIABETES
DE69829217D1 (en) DEVICE FOR THE THERAPEUTIC TREATMENT OF BLOOD VESSELS
EP1185696A4 (en) Antisense oligonucleotide modulation of human protein kinase c-delta expression
WO2004085614A3 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof
WO2001023562A3 (en) Osteoprotegerin regulatory region
ATE255411T1 (en) HYALURONIC ACID RECEPTOR BINDING SUBSTANCES AND THEIR USE FOR THE TREATMENT OF TUMORS AND RESTENOSIS
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
ATE293994T1 (en) MULTIVALENT RECOMBINANT ANTIBODIES FOR THE TREATMENT OF HRV INFECTIONS
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
AU2001261674A1 (en) Treatment methods using 17906 and uses therefor
Callahan Hypnosis: Trick or treatment?
EP1438389A4 (en) Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 14, 19, 22, 26, 29, 32, 34, 37, 39, 42, 45, 51, 52, 59, 64, 69, 78, 81, 84, 85 AND 89, DESCRIPTION, REPLACED BY NEW PAGES 14, 19, 22, 26, 29, 32, 34, 37, 39, 42, 45, 51, 52, 59, 64, 69, 78, 81, 84, 85 AND 89; PAGES 93 AND 100, CLAIMS, REPLACED BY NEW PAGES 93 AND 100

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP